Mylan N.V. (MYL) Q3 2019 Earnings Call Transcript
MYL earnings call for the period ending September 30, 2019.
Mylan
MYL
MYL
$17.24
-$0.37
-2.1%
BATS BZX Real Time Price as of November 11, 2019, 4:00 p.m. EST
View Interactive MYL Charts
The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.
News & Analysis: Mylan
The Fool has written over 200 articles on Mylan.
Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
What Happened in the Stock Market Today
Mylan plans to merge with a spinoff from Pfizer, and Merck had more good news about its blockbuster cancer drug.
Mylan's Mixed 2nd-Quarter Results Overshadowed by News of Its Upjohn Merger
The drugmaker's revenue improved in the second quarter with new product launches, but higher spending weighed on its earnings.
Why Mylan Stock Is Jumping Today
A proposed combination with Pfizer's Upjohn unit is exciting Mylan shareholders.
Stock Market News: Pfizer and Mylan Make a Deal; Chipotle Looks Tasty
Stocks were mixed on Wall Street Monday morning.
Pfizer Closes in on a Major Spinoff
The pharmaceutical giant will reportedly combine its legacy products business with generic drug major Mylan.
Here's Why Generic-Drug Manufacturers Lost As Much As 43.2% in May
The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.
Here's Why Generic-Drug Manufacturers Were Down Monday
Forty-four states have brought a lawsuit against the industry.
Mylan N.V. (MYL) Q1 2019 Earnings Call Transcript
MYL earnings call for the period ending March 31, 2019.
